Results 241 to 250 of about 101,499 (309)

Fenofibrate potentiates the therapeutic efficacy of EZH2 inhibitors on melanoma via TRIM21‐ and OTUD4‐mediated EZH2 ubiquitination

British Journal of Pharmacology, Volume 183, Issue 11, Page 2675-2694, June 2026.
Background and Purpose EZH2 (enhancer of zeste homologue 2) inhibitors are an emerging class of drugs that target epigenetic regulation. However, their efficacy in solid tumours has been limited, partly due to drug‐induced upregulation of fatty acid synthesis.
Rui Cheng, Yuanjun Tang, Xuedi Cao, Xiaotong Yu, Zhanya Huang, Yunyun Guo, Renjing Jin, Yan Wang, Yang Liu, Lixiang Xue, Yuqing Wang   +10 more
wiley   +1 more source

What Is Your Diagnosis? Multiple Subcutaneous Lumps in a Horse

Veterinary Clinical Pathology, EarlyView.
Federica Meistro, Maria Virginia Ralletti, Riccardo Rinnovati, Alessandro Spadari, Maria Morini   +4 more
wiley   +1 more source

Oral Angiolymphoid Hyperplasia With Eosinophilia Exhibiting Cutaneous‐Type Histopathologic Features: Clinical Regression Following Hormonal Withdrawal and a 50‐Year Review

Journal of Cutaneous Pathology, Volume 53, Issue 6, Page 491-501, June 2026.
Case report of a 30‐year‐old female. Asymptomatic, red‐purple hyperplastic lesion extending from teeth 21 to 25, with bleeding upon manipulation. Differential diagnosis included: inflammatory gingival hyperplasia, plasma cell gingivitis, leukemia, and Wegener's granulomatosis.
Pedro Vinícius Santos de Jesus, Louise Cristina Santos, Gilberth Tadeu Dos Santos Aciole, John Lennon Silva Cunha, Nicole Lonni, Matheus Antoni da Silva Costa, Elena Riet Correa Rivero, Rogério Gondak, Ricardo Luíz Cavalcanti de Albuquerque‐Júnior   +8 more
wiley   +1 more source

Management of Primary Refractory Diffuse Large B‐Cell Lymphoma in Patients Unsuitable for CAR T‐Cell Therapy

European Journal of Haematology, Volume 116, Issue 6, Page 771-784, June 2026.
ABSTRACT Primary refractory Diffuse Large B‐Cell Lymphoma is associated with poor outcomes and limited responsiveness to conventional salvage therapies. Although CAR T‐cell therapy represents the standard of care in this setting, a substantial proportion of patients cannot receive it despite meeting disease‐related criteria. In this review, “unsuitable”
Santino Caserta, Enrica Antonia Martino, Mamdouh Skafi, Maria Eugenia Alvaro, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Characteristics and overall survival in patients with T1 melanoma: A nationwide matched cohort study

International Journal of Cancer, Volume 158, Issue 10, Page 2581-2591, 15 May 2026.
What's New? Thin cutaneous malignant melanoma has an excellent ten‐year melanoma‐specific survival of 93%–97%. Moreover, the incidence of melanoma is higher among individuals with high socioeconomic status, which may protect them from other diseases. This nationwide matched cohort study found that patients with thin cutaneous malignant melanoma have a ...
Ylva Naeser, Rasmus Mikiver, Karolin Isaksson, Mats Lambe, Gustav J. Ullenhag   +4 more
wiley   +1 more source

Correlation of the differential expression of PIK3R1 and its spliced variant, p55α, in pan‐cancer

Molecular Oncology, Volume 20, Issue 5, Page 1299-1322, May 2026.
PIK3R1 undergoes alternative splicing to generate the isoforms, p85α and p55α. By combining large patient datasets with laboratory experiments, we show that PIK3R1 spliced variants shape cancer behavior. While tumors lose the protective p85α isoform, p55α is overexpressed, changes linked to poorer survival and more pronounced in African American ...
Ishita Gupta, Yang Song, Madeleine Ndahayo, Anirudh Saxena, Theresa Guo, Dylan Z. Kelley, Jessica Gore, Andrew Hennigan, Alexa Anderson, John C. Papadimitriou, Daria A. Gaykalova   +10 more
wiley   +1 more source

Beyond CD30: Dual‐Targeting of Malignant and Regulatory T Cells by Brentuximab Vedotin Remodels the Lymphoma Microenvironment and Overcomes Resistance via BCL2 Inhibition in Mycosis Fungoides

Advanced Science, Volume 13, Issue 26, 8 May 2026.
Single‐cell RNA analyses of paired lesions from CD30+ mycosis fungoides patients demonstrate that brentuximab vedotin (BV) induces immunogenic cell death in both CD30+ and CD30− malignant T cells. BV also targets regulatory T cells and remodels tumor microenvironment, while resistance is driven by impaired IFN responses, drug efflux, and BCL2 ...
Yi Jiang, Pan Lai, Mingjia Li, Yujie Wen, Mengzhou Cao, Yu Xiao, Zhuojing Chen, Jingru Sun, Yang Wang   +8 more
wiley   +1 more source

Immune Checkpoint Inhibitors and Immunomodulators for Cancer Immunotherapy: Insights Into Resistance and Therapeutic Strategies

Advanced Science, Volume 13, Issue 25, 4 May 2026.
The schematic diagram illustrates the roles of novel immune checkpoints, immunomodulatory factors, cell death and multimodal technologies in cancer immunotherapy. Abstract Cancer immunotherapy has redefined cancer treatment. However, the molecular and cellular basis of immune evasion and therapeutic resistance remains incompletely understood.
Fangquan Chen, Yang Yu, Xiutao Cai, Junhao Lin, Ruirui Liang, Rui Kang, Daolin Tang, Jiao Liu   +7 more
wiley   +1 more source

Cutaneous Lymphoma

Annals of Oncology, 1999
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Cutaneous lymphomas

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2007
SummaryCutaneous lymphomas are rare skin diseases. They must be differentiated from secondary skin infiltrates by primary nodal lymphomas. Primary cutaneous lymphomas can be classified into B‐ and T‐cell lymphomas and hematodermic neoplasms; they usually possess a favorable prognosis and run a chronic course. Treatment is dependent on stage.
Reinhard, Dummer, Rudolf, Stadler, Wolfram, Sterry   +2 more
openaire   +4 more sources